# A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

> **NCT03597295** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 94 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Anal Canal

## Interventions

- **DRUG:** Retifanlimab

## Key facts

- **NCT ID:** NCT03597295
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-08
- **Primary completion:** 2020-06-08
- **Final completion:** 2021-11-10
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03597295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03597295, "A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03597295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*